Saturday, June 29, 2024
AQEMIA, a leader in AI-driven drug discovery, has achieved a significant research milestone in collaboration with Servier, an international pharmaceutical company, targeting an unmanageable immune-oncology target.
Utilizing quantum and statistical physics-based calculations, AQEMIA identified a set of molecules within a few months that effectively interact with the previously untargeted immune-oncology marker. This achievement triggers an undisclosed payment to AQEMIA.
"We are proud of this milestone, showcasing AQEMIA's advanced AI and physics-driven approach in developing novel molecules to address critical therapeutic gaps, particularly in immune-oncology," said Dr. Maximilien Levesque, CEO and co-founder of AQEMIA. "In collaboration with Servier, our efforts have led to promising molecules demonstrating efficacy both in vitro and in vivo."
This milestone marks a continuation of Servier and AQEMIA's successful partnership, initiated in December 2021, aimed at accelerating the discovery of drug candidates in immune-oncology through artificial intelligence and advanced physics.
AQEMIA has developed over a dozen proprietary therapeutic programs spanning oncology, immune-oncology, immunology, inflammation, and central nervous system diseases. Currently, AQEMIA's three most advanced programs are undergoing animal testing for cancer indications.
Source: businesswire.com
